CVS Health (CVS.N) exceeded Wall Street expectations for its first-quarter profit and revenue results on Wednesday and raised its full-year 2026 guidance, driven by a significant recovery in its insurance operations.
The healthcare giant’s robust performance comes despite persistent market anxieties that the Trump administration’s health policies could negatively impact industry profits, a concern CVS managed to navigate through strategic premium hikes and an exit from the Affordable Care Act (ACA) exchange markets.
The company now forecasts full-year 2026 profit to be between $7.30 and $7.50 per share, an increase from its previous guidance of $7.00 to $7.20. Revenue for the year is expected to reach at least $405 billion, up $5 billion from prior estimates, a change CVS CFO Brian Newman attributed largely to “tailwinds” within the Aetna insurance unit. Following the report, shares of the company rose more than 7% in Wednesday trading.
The health benefits segment, which includes Aetna, was a primary driver of the quarter’s success as its operating income surged 53% to $1.05 billion. A critical industry metric, the medical benefit ratio (MBR)—measuring medical expenses paid against premiums collected—improved to 84.6% from 87.3% a year earlier, outperforming the 86.3% ratio that analysts had anticipated. This improvement was supported by organizational efficiencies and the absence of a premium deficiency reserve that had impacted the prior year’s results.
Performance remained strong across all major business divisions during the quarter. The health services segment, which includes the pharmacy benefits manager Caremark, generated $48.24 billion in revenue, representing an 11% increase.
Meanwhile, the pharmacy and consumer wellness division reported sales of $31.99 billion, remaining relatively flat compared to the previous year. Overall, the company posted adjusted earnings of $2.57 per share on total revenue of $100.43 billion, both of which significantly beat analyst projections of $2.20 per share and $95.09 billion in revenue.
The quarterly results reflect continued progress in a broader turnaround strategy that includes $2 billion in cost reductions, the closure of underperforming retail locations, and efforts to lower expenses within privately run Medicare Advantage plans. Newman noted that the company aimed to set “realistic, reasonable targets” and has successfully found pathways to outperform them for several consecutive quarters.
While executives expressed confidence in the 2026 outlook, they maintained a prudent stance, noting that medical costs across the healthcare sector remain elevated.